SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France

09 December 2022 | Friday | News

Cenobamate (ONTOZRY®), for the treatment of uncontrolled focal-onset seizures in adults, is now available in 5 major European countries – Germany, the UK, Italy, Spain, France – and 10 other key markets
Image Source : Public Domain

Image Source : Public Domain

SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that its European partner Angelini Pharma, an international pharmaceutical company part of the privately held Italian Angelini Industries, has launched cenobamate in France.

Cenobamate – under the brand name ONTOZRY® – has been commercialized in five major European countries such as Germany, the UK, ItalySpain, and France, accounting for about 73 percent of the total value of the continent's epilepsy market.[1] It is also available in 10 other key European markets, including Switzerland and Belgium.

Cenobamate was approved by the European Commission (EC) in March 2021 for the adjunctive treatment of focal-onset seizures with or without secondary generalization in adult patients who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products.

Following the EC's marketing authorization for cenobamate, Angelini Pharma launched the anti-seizure medication in GermanyEurope's largest pharmaceutical market, in June 2021, and launched in the UK, Europe's largest epilepsy market, in November 2021, following the Medicines and Healthcare products Regulatory Agency's approval.

Cenobamate was discovered by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science, which have forged a partnership with Angelini Pharma for the European markets.


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in